TEMPLE, Texas--(BUSINESS WIRE)--March 2, 2006--Scott & White has been named as the site for the first Phase I clinical trial of a novel investigational cancer drug aimed at recurrent prostate cancer. Protox Therapeutics, Inc., a Canadian company, developed the drug in Temple and has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with testing. It will be the first clinical trial to be conducted at the new Cancer Research Institute at Scott & White.
